ACTRN12613001304729
Recruiting
未知
A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants
ARES Collaborative0 sites2,000 target enrollmentNovember 22, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Significant haemorrhage
- Sponsor
- ARES Collaborative
- Enrollment
- 2000
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients presenting with significant haemorrhage, thromboembolism or require anticoagulation reversal for urgent surgery and/or a procedure and have taken a NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin within the last 7 days.
Exclusion Criteria
- •Patients who have minor haemorrhage responding to local measures not requiring admission, blood testing or change in anticoagulant management.
- •Patients who are unable to have objective testing for recurrence of thromboembolism.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A multicenter, prospective observational study of new criteria for sepsis (Sepsis-3)Sepsis (sepsis-3 criteria)JPRN-UMIN000036349Japanese Association for Acute Medicine600
Completed
Not Applicable
A multicenter, prospective observational study of treatment and prognosis in patients with primary small bowel cancerSmall bowel cancerJPRN-UMIN000030361ational Hospital Organization Okayama Medical Center54
Completed
Not Applicable
A multicenter, prospective observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel for patients with advanced non-small cell lung cancer (CJLSG 1602)JPRN-UMIN000026927Central Japan Lung Study Group (CJLSG)35
Recruiting
Not Applicable
A prospective, multicenter, observational study of the effects of SGLT2 inhibitors/ SPPARMalpha combination therapy on liver function in patients with type 2 diabetes and dyslipidemiatype 2 diabetes and dyslipidemiaJPRN-UMIN000043716niversity of Miyazaki50
Recruiting
Not Applicable
Polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphomaDiffuse large B-cell lymphomDLBCLDLBCJPRN-jRCT1071220082Kato Koji500